Welcome to our dedicated page for Aptevo Therapeutics news (Ticker: APVO), a resource for investors and traders seeking the latest updates and insights on Aptevo Therapeutics stock.
Aptevo Therapeutics Inc. develops clinical-stage immune-oncology therapeutics for cancer using its proprietary ADAPTIR and ADAPTIR-FLEX platform technologies. News about APVO centers on mipletamig, its CD123 x CD3 program for acute myeloid leukemia, including clinical data, safety observations, orphan drug designation for AML, and combination studies with venetoclax and azacitidine.
Company updates also cover pipeline expansion into bispecific, multispecific and trispecific candidates, solid-tumor work such as ALG.APV-527, conference presentations, financing arrangements, operating results, shareholder voting matters, and governance changes tied to Aptevo’s public-company structure.
Aptevo Therapeutics (Nasdaq: APVO) announced a $2.75 million securities offering priced at-the-market under Nasdaq rules. The offering includes 5,339,806 shares of common stock or pre-funded warrants and warrants to purchase 10,679,612 shares at $0.515 per share. The offering is expected to close around July 1, 2024, with gross proceeds estimated at $2.3 million. The net proceeds will be used for clinical development, working capital, and general corporate purposes. Additionally, existing warrants issued in August 2023, November 2023, and April 2024 will be amended to have a reduced exercise price of $0.515 per share.
Aptevo Therapeutics (Nasdaq: APVO), a clinical-stage biotech firm, is attending the BIO International Convention in San Diego from June 3-6, 2024. The conference, the largest in the biotechnology sector, is projected to draw over 18,000 attendees globally. Representing Aptevo are Dr. Michelle N. Nelson, Director of Immunobiology, and SoYoung Kwon, SVP, General Counsel, and Head of Business Development. Aptevo specializes in immuno-oncology therapeutics using its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platforms.
Aptevo Therapeutics (NASDAQ: APVO) announced its participation in The Protein & Antibody Engineering Summit (PEGS) in Boston, MA, where they will present their strategies for designing bispecific drug candidates. Dr. Peter Pavlik, Senior Director of Protein Engineering, will lead the session, focusing on early functional screening and multiple screening formats to predict outcomes. The company has developed a portfolio of candidates, including clinical-stage APVO436 and ALG.APV-527 and preclinical APVO603, APVO711, and APVO442. Recent clinical updates include a breast cancer patient in the ALG.APV-527 trial showing stable disease for over eleven months and plans to start a dose optimization trial for APVO436 in AML patients in Q2 2024.
Aptevo Therapeutics Inc. reported positive outcomes from its clinical trials, with a breast cancer patient showing stable disease for over eleven months on a higher dose level. The company is set to start a dose optimization trial for APVO436 in 2Q 2024. Financially, Aptevo's cash position was $10.3 million as of March 31, 2024, with reduced research and development expenses and general administrative expenses. However, the company reported a net loss of $6.8 million for the quarter.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.